ACADIA Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ACADIA Pharmaceuticals Inc.
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.
Small-to-medium-sized companies launching their first or one of their only commercial products faced a particular difficult time during the pandemic. In the second quarter earnings calls, some of these SMEs are seeing momentum as the most serious COVID headwinds resolve but others are contending with ongoing challenges. [Check back tomorrow for Part 2 on companies experiencing continuing challenges.]
Artificial Intelligence has been hyped as a game changer in drug discovery for the last five years. How far has it come, and how far can it go? In Vivo talks to some of the key players that are creating and shaping the future of the industry.
- Other Names / Subsidiaries
- Receptor Technologies
- CerSci Therapeutics